ArticleJournal of inflammation research2026
Tocilizumab Treatment in Refractory Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Case Report and Literature Review.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although most patients with autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) respond to first-line immunotherapy, a subset is refractory to conventional treatments and experiences poor outcomes. This study evaluates the efficacy of tocilizumab in such refractory cases, based on clinical experience and literature review. We retrospectively analyzed a 17-year-old female with GFAP-A who presented with fever, headache, coma, language and emotional disturbances, and motor deficits. Brain magnetic resonance imaging showed T2/FLAIR hyperintensity and swelling in the bilateral basal ganglia and left hippocampus. Anti-glial fibrillary acidic protein (GFAP) antibody was positive in both serum and cerebrospinal fluid. The patient was refractory to high-dose corticosteroids, intravenous immunoglobulin, with only a transient response to rituximab. However, after five infusions of tocilizumab, she demonstrated significant improvement in language, motor function, mood, and remained in stable remission during follow-up, with no severe adverse events. A literature review identified a previously reported case of GFAP-A coexisting with anti-N-methyl-D-aspartate receptor encephalitis that similarly showed only a partial response to first-line immunotherapies before achieving marked clinical improvement after five cycles of tocilizumab. These findings suggest that tocilizumab may represent an effective therapeutic option for refractory GFAP-A, significantly improving cognitive and neuropsychiatric outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.